The best porn streaming videos site,hardcore,anal,amateur,teen,milf all fuck porn here, hd porn
hd porno izle
Company Presentations | Stem Cell Meeting on the Mesa

Company Presentations

Company Presentations

The deadline to apply for a company presentation at this year’s Partnering Forum passed on Friday, June 19, 2015. Check back in early August to see the 50+ top cell therapy, gene therapy and tissue engineering companies who will be selected to present at the 2015 conference.

Selection Criteria:

OrangeCells-25 Company must be an ARM member in good standing. Non-members will only be considered if space is available.

OrangeCells-25The information being presented is current and describes key technological advances and/or clinical milestones that will lead to the progression of the company and the field over the next 12 months.

OrangeCells-25CEO or senior-level member of the company management team MUST be available to present.

Benefits of Presenting:

OrangeCells-25Opportunity to feature your company in front of more than 450 top executives in the regenerative medicine and advanced therapies field

OrangeCells-25Extensive exposure to all major industry players including big pharma, large biotech, disease philanthropies, investors and major research institutions

OrangeCells-25Opens the door for potential funding and partnership deals

2014 Company Presenters

BioLife-Solutionsblue bird bio


Dominick Colangelo, President & CEO
Oct. 7 | 10:15am | La Jolla Ballroom 1
Ann Arbor, MI
Founded in 1989, Aastrom Biosciences is dedicated to the development of stem cell treatments for critical cardiovascular diseases. Aastrom is currently evaluating its autologous cellular therapies in U.S. clinical trials in the treatment of dilated cardiomyopathy (DCM). These critical diseases are associated with significant morbidity and mortality and very limited treatment options.


Daniel Lim, M.D., Ph.D., Assistant Professor of Neurological Surgery, University of California, San Francisco
George Yu, President & CEO, Accurexa
Oct. 8 | 4:45pm | La Jolla Ballroom 2
San Francisco, CA
Accurexa is developing a medical stereotactic device, which the Company believes has the potential to significantly improve the delivery of stem cells into the human brain and enhance the efficacy of a wide range of stem cell therapeutics. Accurexa licensed the device from the University of California, San Francisco (UCSF). Unlike, currently available neurosurgical devices using a straight, rigid needle, Accurexa’s device enables the radial deployment of a flexible delivery catheter to large and anatomically complex brain targets through a single initial brain penetration which can improve the accuracy of cell delivery, reduce the risk of complications, and increase patient safety.


James Noble, CEO
Oct. 7 | 11:30am | La Jolla Ballroom 1
Oxford, UK
Established in July 2008 with a research base in Oxford, UK and a clinical base in Philadelphia, US, Adaptimmune is focused on the use of T cell therapy to treat cancer and infectious disease. It aims to utilise the body’s own machinery – the T cell – to target and destroy cancerous or infected cells by using engineered, increased affinity T cell receptor (TCRs) as a means of strengthening natural patient T cell responses. Adaptimmune undertakes all of its own research and development using proprietary T cell receptor engineering technology co-developed with its sister company Immunocore Ltd (formerly Avidex/MediGene) and exclusively licensed for T cell therapy. Backed by private investors, Adaptimmune is now in the clinic in the US, in multiple cancer indications with its engineered TCR to the NY-ESO-1/LAGE-1 cancer testis antigen.


Daniel Menichella, VP & Chief Business Officer
Oct. 7 | 2:15pm | La Jolla Ballroom 1
Alachua, FL
AGTC is developing cures for rare lung and eye diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, the Company is use cutting-edge techniques to develop treatments for patients that have diseases caused by broken genes. AGTC uses AAV gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide.


Jane Lebkowski, Ph.D., President of R&D
Oct. 7 | 11:00am | La Jolla Ballroom 1
Menlo Park, CA
Asterias Biotherapeutics is developing therapies based on pluripotent stem cells to treat diseases or injuries having major unmet needs. Asterias’ initial focus is on two clinical stage programs including oligodendrocyte progenitor cells (AST-OPC1) for spinal cord injuries and antigen-presenting allogeneic dendritic cells (AST-VAC2) for lung cancer. In October of 2013, Asterias acquired the cell therapy assets of Geron Corporation. These assets included INDs for the clinical stage AST-OPC1 and AST-VAC1 programs, banks of cGMP-manufactured AST-OPC1 drug product, cGMP master and working cell banks of human embryonic stem cells. They also included over 400 patents and patent applications filed worldwide including broad issued claims to fundamental platform technologies for the scalable growth of pluripotent stem cells and compositions of matter for several hESC-derived therapeutic cell types, research cell banks, customized reagents and equipment, and various assets relating to the AST-VAC2 program and preclinical programs in cardiology and orthopedics.


Gil Van Bokkelen, Ph.D., Chairman & CEO
Oct. 7 | 11:45am | La Jolla Ballroom 1
Cleveland, OH
Athersys is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. The Company’s focus is on the treatment of medical conditions where there is significant unmet clinical need. Athersys is developing MultiStem®, a patented, adult-derived “off-the-shelf” stem cell product platform for multiple disease indications in the areas of inflammatory and immune, neurological and cardiovascular disease. The Company has two ongoing clinical studies – a Phase II study in ulcerative colitis being conducted with Pfizer and a Phase II study in ischemic stroke – and overall five clinical-stage programs in inflammatory bowel disease, stroke, graft-versus-host disease, acute myocardial infarction and solid organ transplant. Athersys has forged a network of strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research and clinical institutions, in the U.S. and Europe to further develop its platform and products.


Hans Hull, SVP, Legal & Corporate Development
Oct. 8 | 2:00pm | La Jolla Ballroom 1
Menlo Park, CA
Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Using a next generation gene therapy platform, the Ocular BioFactory™, the Company is developing products designed to provide long-term benefit or a functional cure by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye.


Stephanie Piecewicz, Ph.D., Product Manager
Oct. 7 | 5:15pm | La Jolla Ballroom 2
San Francisco, CA
Bell Biosystems is pioneering the use of synthetic organelles to accelerate product development in regenerative medicine and oncology. Organelles are nature’s way of adding functions to cells and Bell Biosystems has discovered a way to make synthetic organelles to add new, useful functions to cells. The Company’s first organelle, the Magnelle, is a living magnetic resonance imaging contrast agent that can divide with cells. Using non-invasive MRI, researchers and companies can image and track Magnelle labeled cells and cell progeny longitudinally because Magnelles do not dilute like traditional MRI contrast reagents do during cell division. This technology can enable tracking of cell engraftment, distribution and persistence, and therefore monitor safety and efficacy of cell therapies.


Mike Rice, CEO
Oct. 8 | 2:15pm | La Jolla Ballroom 2
Bothell, WA
BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues and organs. The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the regenerative medicine, biobanking and drug discovery markets. BioLife’s biopreservation media products are serum-free and protein-free, fully defined and are formulated to reduce preservation-induced cell damage and death. The Company’s enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues and organs. BioLife also performs contract aseptic media formulation, fill and finish services. To date, the Company’s proprietary biopreservation media products have been incorporated into over 100 hospital-approved and clinical trial stage regenerative medicine products and therapies.


Faraz Ali, VP, Commercial Development
Oct. 8 | 1:30pm | La Jolla Ballroom 1
Cambridge, MA
bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases. bluebird bio has two clinical-stage programs in development. The most advanced product candidate, Lenti-D, is in a recently-initiated Phase II/III study, the Starbeam Study, for the treatment of childhood cerebral adrenoleukodystrophy (CCALD), a rare, hereditary neurological disorder affecting young boys. The next most advanced product candidate, LentiGlobin, is currently in two Phase I/II studies, one in the U.S. (the Northstar Study) and one in France (HGB-205), for the treatment of beta-thalassemia major. The Phase I/II HGB-205 study also allows enrollment of patients with sickle cell disease, and bluebird bio is planning a separate U.S. sickle cell disease trial (HGB-206).


Linda Marbán, Ph.D., CEO
Oct. 7 | 10:45am | La Jolla Ballroom 1
Beverly Hills, CA
Los Angeles-based Capricor Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of regenerative medicine and large molecule products for the treatment of diseases. Capricor’s lead product candidate, an allogeneic cardiosphere-derived cell (CDC) product, CAP-1002, aims to attenuate and potentially improve damage to the heart caused by a heart attack and is currently under evaluation in the Phase I/II ALLSTAR clinical trial of patients 30-days to 1-year after a heart attack. Additionally, Capricor plans to explore development of exosome technology as a next generation regenerative medicine platform in a variety of cardiovascular and non-cardiovascular areas. Groundbreaking preclinical research has demonstrated that exosomes extracted from Capricor’s CDCs reduced scar tissue caused by a heart attack and prompted myocardial regeneration in preclinical models of ischemic heart disease.


Christian Homsy, M.D., CEO
Oct. 8 | 4:45pm | La Jolla Ballroom 1
Mont-Saint-Guibert, Belgium
(CARD:EN Brussels)
Cardio3 BioSciences is a leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The Company’s lead product candidate, C-Cure®, is a highly innovative stem cell approach for the treatment of heart failure, one of the world’s most pressing unmet medical needs. Generated through a proprietary technological platform, the C3BS-CQR-1 programme is designed to direct the patient’s own stem cells into new heart cells with the potential to rebuild the heart. Cardio3 BioSciences has also developed C-Cath®ez, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium. Cardio3 BioSciences was founded in July 2007 and is based in Mont-Saint-Guibert in the Walloon region of Belgium. The Company leverages research collaborations in the U.S. and in Europe with Mayo Clinic.


Clive Svendsen, Ph.D., Director & Professor, Board of Governors Regenerative Medicine Institute
Oct. 8 | 4:30pm | La Jolla Ballroom 2
Los Angeles, CA
(Non-Profit Hospital)
Through funding from the California Institute for Regenerative Medicine (CIRM), Cedars Sinai Regenerative Medicine Institute is half-way through the preclinical and manufacturing process to take the world’s first combined stem cell and gene therapy product to treat ALS to the clinic. The product is a human neural progenitor line derived from fetal tissue expanded using a unique “chopping” method that avoids cell dissociation and maintains the cultures in an in vivo environment – closely adapted to that of the living host CNS. They are engineered to produce the powerful growth factor GDNF and then transplanted into the spinal cord of rodents and pigs to test for toxicity, tumorigenicity and migration. Following IND submission, the Institute will plan an 18 patient clinical trial at Cedars-Sinai using a new minimally invasive injection device with a unique unilateral design powered to show changes in progression in the treated limb. Cedars Sinai is partnering with uniQure for the next phase of commercialization of this product.


Krisztina Zsebo, Ph.D., CEO
Oct. 8 | 4:15pm | La Jolla Ballroom 1
San Diego, CA
Celladon is a clinical-stage biotechnology company developing novel therapies for diseases with tremendous unmet medical needs. The Company’s lead gene therapy product candidate MYDICAR® targets calcium dysregulation in cardiomyocytes by increasing SERCA2a enzyme levels in advanced heart failure. In a placebo controlled Phase IIa trial, MYDICAR® demonstrated an 88% reduction of hospitalizations for heart failure and a trend in improved overall survival. Benefit in clinical outcomes was also supported by improvement in patients’ heart failure symptoms, exercise tolerance, serum biomarkers and cardiac function. MYDICAR® recently received Breakthrough Therapy designation by the FDA, and the EMA indicated that if MYDICAR® demonstrates a substantial and highly significant treatment effect, and no untoward effects attributable to MYDICAR® are observed, a safety database of approximately 205-230 MYDICAR® treated subjects may be sufficient to allow for acceptance of an MAA. MYDICAR® is currently in a 250-patient Phase IIb trial with results expected in April 2015.


Robert Palay, CEO
Oct. 8 | 4:30pm | La Jolla Ballroom 1
Madison, WI
Cellular Dynamics International is a leading developer of fully functional human cells derived from induced pluripotent stem (iPS) cells. The Company’s iCell® and MyCell® product lines provide industrial quantities of high quality, highly pure human cells enabling disease modeling, drug discovery, toxicity testing and regenerative medicine research.


Matthew Plavan, CEO
Oct. 7 | 2:30pm | La Jolla Ballroom 2
Rancho Cordova, CA
Cesca Therapeutics is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is a leader in developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.


Koji Kuchiishi, Chairman, President & CEO
Oct. 7 | 11:00am | La Jolla Ballroom 2
Tokyo, Japan
Founded in 2010, Cyfuse Biomedical K.K. is a Japan-based start-up focused on scaffold-free 3D tissue engineering. Cyfuse successfully developed the bio 3D printer Regenova, a state-of-the-art robotic system that enables fully automated fabrication of three-dimensional artificial tissues from living cells. The Company’s goal is to facilitate innovative therapeutic approaches through new bioengineering technologies to make regenerative medicine a reality for patients around the world.


Martin Rosendale, CEO
Oct. 7 | 5:45pm | La Jolla Ballroom 1
Gaithersburg, MD
Cytomedix is an autologous regenerative therapies company commercializing innovative platelet technologies for wound care. The Company markets the AutoloGel™ System, a device for the production of autologous platelet rich plasma (PRP) gel for use on a variety of exuding wounds.


Flagg Flanagan, Chairman & CEO
Oct. 7 | 11:30am | La Jolla Ballroom 2
Salt Lake City, UT
DiscGenics is a biotechnology company developing advanced spinal therapeutics to treat patients with diseases of the intervertebral disc. DiscGenics is the only company to utilize therapeutic progenitor cells derived from disc to treat the disc. The Company’s allogeneic methodology allows DiscGenics to derive many doses from each adult tissue donation. The Company’s first product, Injectable Discogenic Cell Therapy (IDCT), is in preclinical development for the treatment of moderate degenerative disc disease. This cellular treatment offers a cost-effective and non-surgical solution to patients who currently have few treatment options. Further, the treatment may delay the progression towards costly and often ineffective surgical interventions necessary at the late stages of degeneration. A follow-on product utilizing a different scaffold carrier will be for post-discectomy patients and is currently being researched.


Sandra Glucksmann, Ph.D., Chief Operating Officer
Oct. 8 | 2:30pm | La Jolla Ballroom 1
Cambridge, MA
Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies. The company’s mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas was founded in 2013 with $43 million in Series A venture capital financing led by leading health care venture capital firms Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.


John Maslowski, VP, Scientific Affairs
Oct. 7 | 2:30pm | La Jolla Ballroom 1
Exton, PA
Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation (NYSE: XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage preclinical development for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma.


Gail Naughton, Ph.D., Chairman & CEO
Oct. 7 | 10:15am | La Jolla Ballroom 2
San Diego, CA
Histogen is a regenerative medicine company manufacturing and developing innovative therapies based on the products of cells grown under simulated embryonic conditions. Through Histogen’s proprietary technology process, including conditions of low oxygen and suspension, newborn cells are encouraged to naturally produce vital proteins and growth factors which are characteristic of young, rapidly developing tissue and which can stimulate stem cells in the patient’s own body to regenerate into new tissue. Using this patented tissue-engineering platform, Histogen has developed a rich pipeline of unique commercialization opportunities for both aesthetic and therapeutic applications. The Company’s lead product, Hair Stimulating Complex (HSC) has shown success in two Company-sponsored clinical trials as an injectable treatment for alopecia. In addition, Histogen’s human multipotent cell conditioned media can be found in skincare products including ReGenica, which is distributed by Suneva Medical in partnership with Obagi Medical Products.


Tom Ulich, M.D., Chief Scientific Officer
Oct. 7 | 3:00pm | La Jolla Ballroom 1
Cambridge, MA
InVivo Therapeutics is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The Company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology (MIT), and Joseph Vacanti, M.D., who is affiliated with Massachusetts General Hospital. InVivo is developing biocompatible neuro-spinal scaffolds to treat acute SCI and neuro-spinal scaffolds plus stem cells to treat chronic SCI. Data on InVivo’s scaffold and scaffold plus stem cells technology was first published in the Proceedings of the National Academy of Sciences (PNAS) in 2002 and has since been demonstrated to successfully promote functional recovery following traumatic spinal cord injury in several models. Data from InVivo’s pilot non-human primate study was published in the Journal of Neuroscience Methods in 2010, which earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine.


Mitchell Seyedin, Ph.D., Executive Chairman
Oct. 7 | 11:15am | La Jolla Ballroom 2
St. Louis, MO
A leading regenerative medicine company focused on developing novel orthobiologic products, the Company has two late-stage development programs targeting areas of significant unmet medical need in spine and sport medicine. The lead product candidates are NuQu for the treatment of discogenic back pain and RevaFlex for articular knee cartilage repair and restoration. ISTO’s cartilage regeneration platform uses juvenile cartilage cells that are expanded using a proprietary manufacturing process. Juvenile cartilage cells possess vastly superior regeneration potential compared to adult cartilage cells. In addition to the cartilage regeneration platform, ISTO has developed and markets a synthetic biomaterial for bone generation which is primarily used in spinal fusion applications. InQu is FDA 510(k) cleared for use as a bone graft extender for fusion in all areas of the spine. InQu has been used in over 30,000 procedures and has demonstrated an excellent safety profile.


Henry Klassen, M.D., Ph.D., Founder
Oct. 7 | 5:30pm | La Jolla Ballroom 2
Newport Beach, CA
jCyte is developing a progenitor cell-based product for use in retinal degenerative diseases, specifically blinding conditions involving the loss of photoreceptors. The initial target disease is the orphan disease known as retinitis pigmentosa (RP) and the follow-on disease target is age-related macular degeneration (AMD). jCyte’s novel translational work has received substantial support from the California Institute of Regenerative Medicine (CIRM), first as an Early Translational Grant in the amount of $4 million in 2010 and then in the form of a Disease Team Therapy Development Award for an additional $17.1 million in 2012. This funding provides for IND-enabling preclinical work as well as early-stage clinical trials. jCyte is one of a small number of entities pioneering the application of regenerative medicine-based technologies to unmet medical need in the retina. The immediate goal is to obtain regulatory approval from the FDA for clinical testing in retinitis pigmentosa.


Marc Penn, M.D., Ph.D., Founder & Chief Medical Officer
Oct. 8 | 1:45pm | La Jolla Ballroom 2
Cleveland, OH
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. Founded in 2007 with an exclusive license from Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept into Phase II clinical trials for heart failure and critical limb ischemia. The Company’s lead product, JVS-100, is a non-viral DNA plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival, recruiting endogenous stem cells to the damaged region and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential.


Doug Doerfler, President & CEO
Oct. 8 | 1:30pm | La Jolla Ballroom 2
Gaithersburg, MD
MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing and delivery of innovative cell-based therapeutic products. MaxCyte is pioneering the use of mRNA for Chimeric Antigen Receptor (CAR) immunotherapies for solid cancers with Drs. Carl June and Dario Campagna. Early in 2013, MaxCyte received U.S. patent 8,450,112 providing broad coverage for transiently modifying unexpanded cells (specifically, unstimulated resting PBMCs) to express CARs for treating cancer. This approach, building on the work with Dr. June and others and pioneered by MaxCyte, enables the dramatic reduction of costs and processing times (from two weeks to less than one day), leveraging existing leukopheresis infrastructure to create a rapid, truly commercializable and cost-effective form in mRNA CAR cancer therapies.


Antonio Lee, Ph.D., CEO & Managing Director
Oct. 7 | 10:45am | La Jolla Ballroom 2
Rockville, MD
(078160: KOSDAQ)
MEDIPOST is a leading stem cell biotechnology company focused on developing stem cell therapeutics using human Umbilical Cord Blood-derived Mesenchymal Stem Cells (hUCB-MSCs) to meet unmet medical needs such as those related to regenerative or functional recovery of knee articular cartilage, the nervous system, the pulmonary system and hematopoietic transplantation engraftment areas. CARTISTEM® is the world’s first allogeneic stem cell product with a Biologics License Application (BLA) approved by the Ministry of Food and Drug Safety (MFDS) Korea (former KFDA) for the regeneration of knee cartilage for the sufferers of degenerative osteoarthritis. CARTISTEM® contains multi-potent human Umbilical Cord Blood-derived Mesenchymal Stem Cells (hUCB-MSCs) with unique characteristics including not provoking an immune-response when transplanted into unrelated recipients. This allows large-scale manufacturing of CARTISTEM® using freshly isolated MSCs from the voluntarily donated cord blood units.


Donna Skerrett, M.D., Chief Medical Officer
Oct. 7 | 10:30am | La Jolla Ballroom 1
Melbourne, Australia
Mesoblast Limited is developing novel biotherapeutics derived from its proprietary adult stem cell-based technologies. The Company’s technology platforms have the potential to deliver a diverse portfolio of clinical-stage products to treat a broad range of conditions with major unmet medical needs. Its strategic product development focus is in four major and distinct areas – systemic inflammatory conditions, cardiovascular diseases, orthopedic diseases of the spine and oncology conditions. Mesoblast’s corporate strategy is to: leverage proprietary cell-based and complementary biologic technologies to develop products for unmet medical needs; bring multiple products to market within a parallel timeframe; underpin future financial growth through investing in manufacturing operations; and enhance the likelihood of commercial success through strategic partnerships. Mesoblast’s strong cash reserves ($242 million at 31 March 2014) enable simultaneous product development with future revenues expected from milestone payments, distribution arrangements and direct sales.


Thomas Koob, Ph.D., Chief Scientific Officer
Oct. 7 | 5:00pm | La Jolla Ballroom 1
Marietta, GA
MiMedx®, the premier processor of regenerative biomaterial products and implants from human amniotic membrane, has distributed hundreds of thousands of amniotic tissue grafts worldwide. Profound clinical outcomes have been achieved in therapeutic areas including ophthalmology, spine, wounds, dental, orthopaedic, surgery, sports medicine and urology. With this innovative allograft that promotes bioactive healing, MiMedx® believes its intellectual property and proprietary processing technique strategically positions the Company as the leader in this area of regenerative medicine.


Stephen Potter, Executive Vice President
Oct. 7 | 11:15am | La Jolla Ballroom 1
New York, NY
NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell-based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

Scott Carmer, Chief Business Officer
Oct. 7 | 5:00pm | La Jolla Ballroom 2
Gaithersburg, MD
NexImmune is an ImmunoOncology company developing products from its proprietary AIMTM technology platform for T cell stimulation. Central to the AIM technology are artificial Antigen Presenting Cells (aAPCs) that have advantages over therapeutic approaches based on cancer vaccines, CART Cells, and TCRs. AIM aAPC products elicit a therapeutically relevant endogenous polyclonal T cell response that does not depend on natural dendritic cells and does not require re-engineering of T cells. AIM aAPCs can be used both in vitro and in vivo for direct T cell antigen-specific stimulation and expansion. AIM101, the Company’s first product, is expected to enter clinical trials in 2016 and will have utility across a broad range of both solid and hematologic tumor types. The AIM technology also has applications in infectious and autoimmune diseases which NexImmune is pursuing through partnerships.


Stephen Chang, Ph.D., VP, R&D
Oct. 8 | 2:30pm | La Jolla Ballroom 2
New York, NY
The New York Stem Cell Foundation (NYSCF) is an independent, non-profit organization founded in 2005 to accelerate cures and treatments through stem cell research. NYSCF employs over 40 researchers at the NYSCF Research Institute in New York, and is an acknowledged world leader in stem cell research and in developing stem cell technologies, including the NYSCF Global Stem Cell Array. Additionally, NYSCF supports another 60 researchers at leading institutions worldwide through its Innovator Programs, including the NYSCF – Druckenmiller Fellowships and the NYSCF – Robertson Investigator Awards. NYSCF focuses on translational research in a model designed to overcome barriers that slow discovery and replaces silos with collaboration. NYSCF researchers have achieved many major discoveries, including the discovery of a clinical cure to prevent mitochondrial diseases, the derivation of the first-ever patient specific embryonic stem cell line and the creation of the first disease model from induced pluripotent stem cells.


Benjamin Shepherd, Ph.D., Pre-clinical Study Director
Oct. 7 | 2:45pm | La Jolla Ballroom 1
San Diego, CA
Organovo designs functional human tissues. The Company’s bioprinting technology enables the creation of 3D tissues that more accurately reproduce native tissues. Organovo’s focus is on developing a range of tissue and disease models for medical research and therapeutic applications.


Lode Debrabandere, Ph.D., CEO
Oct. 7 | 5:15pm | La Jolla Ballroom 1
Columbia, MD
Through over 20 years of research, experience and understanding, Osiris Therapeutics has led the way in mesenchymal stem cell (MSC) science and the clinical application of cellular therapies. From commercializing its first generation implantable product, Osteocel, to achieving the Company’s initial goal, when founded in 1992, of developing the world’s first approved stem cell drug, remestemcel-L for graft versus host disease, Osiris has written the book on regenerative medicine. Today, as the leading stem cell company, Osiris continues to address unmet medical needs with innovative approaches in developing and marketing products in wound care, orthopedics and sports medicine. Never forgetting that the Company’s products are differentiated by scientific excellence, Osiris’ current product line includes Grafix® for acute and chronic wounds, Cartiform®, a viable cartilage mesh for cartilage repair, and OvationOS®, a viable bone matrix used for bone repair and regeneration.


Kyriacos Mitrophanous, Ph.D., Head of Research
Oct. 8 | 1:45pm | La Jolla Ballroom 1
Oxford, United Kingdom
Oxford BioMedica is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company’s technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye, and a unique tumor antigen (5T4), which is an ideal target for anti-cancer therapy.


John Martin, Executive Chairman
Oct. 7 | 3:00pm | La Jolla Ballroom 2
Gordon, Australia
Regeneus is a Sydney-based regenerative medicine company founded in August 2007 that is focused on using the regenerative capacities of adipose-derived cells to develop innovative cell therapies for humans and animals. Regenerative medicine is a rapidly growing multidisciplinary specialty that is focused on the repair or regeneration of cells, tissues and organs. The primary goal is to enhance the body’s natural ability to replace tissue damaged or destroyed by injury or disease.


Dennis Clegg, Ph.D., Co-Founder
Oct. 7 | 5:45 | La Jolla Ballroom 2
Glendale, CA
Regenerative Patch Technologies is a new company whose focus is the development of stem cell based therapies for ocular disease. The Company is a spin-off from academic research at the University of Southern California (USC), California Institute of Technology (Caltech), University of California, Santa Barbara (UCSB) and City of Hope and is funded by the California Institute for Regenerative Medicine (CIRM). Current efforts are aimed at developing a therapy for geographic atrophy / dry age-related macular degeneration. This disease is caused by loss or dysfunction of the retinal pigmented epithelium (RPE), which leads to death of rods and cones in the retina. The product under development (CPCB-RPE1) consists of a sheet of RPE derived from human embryonic stem cells on a synthetic parylene scaffold, which will be surgically implanted into the eye in an out-patient procedure. Led by Mark Humayun (USC), David Hinton (USC) and Dennis Clegg (UCSB), the team is completing IND-enabling studies and is on track to file an IND in Q4 of 2014.


Michael Hunt, CEO
Oct. 7 | 2:15pm | La Jolla Ballroom 1
Guildford, England
ReNeuron is a leading clinical-stage cell therapy development business. Based in the U.K., its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need. ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments. The Company’s therapeutic candidates for stroke disability and critical limb ischemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development. ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer.


David Hall, CEO
Oct. 7 | 11:45am | La Jolla Ballroom 2
Vancouver, BC
RepliCel is a regenerative medicine company focused on autologous cell therapies that address diseases caused by a deficit of healthy cells required for healing and function such as chronic tendinosis, damaged skin and pattern baldness. The Company’s RCT-01 and RCS-01 therapies treat chronic tendinosis and damaged skin using fibroblasts isolated from the sheath of the hair follicle. RCH-01 is another hair follicle derived cell therapy for the treatment of pattern baldness. In all indications, specific cells are isolated, replicated into the millions and delivered back into the patient to reactivate a stalled healing process. These products utilize the Company’s proprietary manufacturing and cell expansion platform. RepliCel is also developing cell injector devices for dermal injections. In addition to addressing the delivery requirements for RCH-01 and RCS-01, they should have applications in many current dermatological injection procedures.


Teresa Leezer, CEO
Oct. 8 | 4:15pm | La Jolla Ballroom 2
Louisville, KY
RhinoCyte, Inc. is a privately owned biopharmaceutical company focused on developing transformational technologies that will change the way neurodegenerative disorders are treated. Founded in 2005, the Company is advancing innovative treatment paradigms that leverage proprietary cell therapies for high unmet clinical needs including Spinal Cord Injury (SCI), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS) Multiple Sclerosis (MS) and Type 1 Diabetes. RhinoCyte leverages novel regenerative therapies to extend and enhance the quality of human life without immunosuppression or genetic manipulation.


Curt Herberts, Senior Director, Corporate Development
Oct. 8 | 1:15pm | La Jolla Ballroom 1
Richmond, CA
Sangamo is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. The Company is a worldwide leader in the development of a proprietary technology platform that enables specific regulation of gene expression and gene modification. The basis of this platform is a naturally occurring class of transcription factors, zinc finger DNA-binding proteins (ZFPs) which can be engineered to drive desired therapeutic outcomes. Engineered ZFPs can be linked to functional domains to create ZFP transcription factors (ZFP TFs) capable of turning genes on or off. The Company can also link ZFPs to nuclease domains to create zinc finger nucleases (ZFNs) which enable precise gene-editing in cells. Engineered ZFNs can modify a cell’s DNA at a precise location, thereby facilitating correction or disruption of a specific gene or the targeted addition of a new DNA sequence.


Jill Helms, Ph.D., Professor of Surgery
Oct. 7 | 10:30am | La Jolla Ballroom 2
Stanford, CA
(Academic Institution)
At Stanford, the goal is to discover new ways to remain fit and vigorous, well into old age. The university has identified and characterized a potent stem cell activator, WNT and shown that it activates both embryonic and adult stem cells in a wide range of assays. With CIRM funding, the university has developed a strategy for activating a patient’s own bone stem cells to reinvigorate the body’s natural regenerative process. The end result is rapid healing, back to the levels appreciated in youth.


Martin McGlynn, President & CEO
Oct. 7 | 3:15pm | La Jolla Ballroom 1
Newark, CA
StemCells, Inc. is engaged in research and clinical development of cell-based therapeutics using the Company’s platform technology, a proprietary highly purified population of human neural stem cells, HuCNS-SC® cells. The Company is developing therapies for central nervous system disorders. The Company completed enrollment in a Phase I/II clinical trial in spinal cord injury and has reported positive data for the first eight patients. The Company is also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD). Both studies release final results next year. StemCells, Inc. is pursuing preclinical studies in Alzheimer’s disease with funding support from the California Institute of Regenerative Medicine (CIRM). In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal childhood myelination disorder, the Company showed preliminary evidence of donor-derived myelination in all four patients. StemCells, Inc. also markets stem cell research products including media and reagents under the SC Proven® brand.


Michael Leek, Ph.D., CEO
Oct. 7 | 2:45pm | La Jolla Ballroom 2
Edinburgh, Scotland
Commercializing the anti-cancer cytotoxicity exhibited by γδ T cells, TC BioPharm is developing an autologous therapy which involves expansion of the cells over a two-three week period to formulate a treatment for a wide-variety of different tumor types. The manufacturing process comprises several steps. The first involves isolation of peripheral blood mononuclear cells; the second involves selection/activation of γδ T cells; the final stage requires culture expansion in a GMP environment, providing therapeutically relevant cell numbers prior to administration. Although there are many different approaches to T cell immunotherapy, the process has a compelling clinical safety and efficacy record, demonstrated by a cohort of published case histories. Moreover, when contrasted with novel immunotherapies such as PDL-1 and CTLA-4 inhibitors being developed by Roche and Bristol Myers Squibb respectively, use of γδ T cells may have a complimentary and synergistic therapeutic benefit.


Sven Lee, Global Director, Sales & Business Development, Cell Processing
Oct. 8 | 2:00pm | La Jolla Ballroom 2
Lakewood, CO
(4543: Tokyo)
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. Terumo believes in the potential of blood to do even more for patients than it does today. This belief inspires the Company’s innovation and strengthens Terumo’s collaboration with customers. Terumo BCT -Unlocking the Potential of Blood.


Eduardo Bravo, CEO
Oct. 7 | 5:30pm | La Jolla Ballroom 1
Leuven, Belgium
(NYSE Euronext: TIG)
TiGenix was founded in 2000 to clinically develop and bring to market novel cell therapeutic products. In 2009, the Company became the first European company to obtain centralized marketing authorization for an Advanced Therapeutic Medicinal Product (ATMP) with its Chondrocelect product, which is currently on the market in various countries in Europe. The Company’s merger with Cellerix in 2011 secured long-term growth through a clinical-stage pipeline of allogeneic adult Mesenchymal Stem Cells (MSCs). The most advanced product of this pipeline is poised to deliver Phase III results in 2015. The Company has been listed on NYSE Euronext Brussels since March 2007. Roughly 70% of the outstanding shares represent free-float, with the remaining shares being in the hands of stable reference shareholders.


Donald Kohn, M.D., Professor
Oct. 7 | 3:15pm | La Jolla Ballroom 2
Los Angeles, CA
(Academic Institution)
Sickle cell disease may be treated with allogeneic hematopoietic stem cell transplantation (HSCT), but is limited by the need to find a suitable matching donor and immunological risks. Stem cell gene therapy can allow an autologous HSCT to be done using the patient’s own bone marrow stem cells without the immune complications. We have developed a lentiviral vector that adds to hematopoietic stem cells a modified version of human beta-globin that prevents sickling of red blood cells. A Phase I clinical trial funded by CIRM Disease team Awards (DR1-01452 and DR3-06945) will be initiated in 2014 to assess feasibility, safety and secondary end-points of efficacy. Stem cell gene therapy may provide a safe and improved therapy for sickle cell disease.


Paul Laikind, Ph.D., President & CEO
Oct. 7 | 2:15pm | La Jolla Ballroom 2
San Diego, CA
ViaCyte, a private company in the field of regenerative medicine, is currently focused on developing a novel cell therapy for the treatment of diabetes. The Company’s lead product candidate, VC-01, is based on the production of pancreatic progenitors derived from human pluripotent stem cells. These cells are implanted in a durable and retrievable encapsulation device called the Encaptra® drug delivery system. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and the Juvenile Diabetes Research Foundation (JDRF).


Jeff Goater, VP, Business Development
Oct. 8 | 1:15pm | La Jolla Ballroom 2
Cambridge, MA
Voyager Therapeutics is developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system. The Company’s founders include scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience. Voyager’s management team has deep expertise and a track record of building exceptional life science companies. The Company has developed a product engine that may transform treatment for a wide range of diseases. Voyager’s pipeline includes VY-AADC01 for Parkinson’s disease, VY-SOD101 for a monogenic form of ALS and VY-FXN01 for Friedreich’s ataxia. Voyager is committed to advancing the field of AAV gene therapy by innovating and investing in areas such as vector optimization and engineering, dosing techniques, as well as process development and production. Voyager is a private company launched in February 2014 with $45 million in Series A venture capital financing from Third Rock Ventures.